Your session is about to expire
← Back to Search
RAIN-32 for Liposarcoma (MANTRA Trial)
MANTRA Trial Summary
This trial is testing a new drug for people with a certain type of cancer that has progressed after trying other treatments. The trial will compare the new drug to a standard treatment to see if the new drug is more effective and has fewer side effects.
- Dedifferentiated Liposarcoma
MANTRA Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowMANTRA Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2008 Phase 2 trial • 271 Patients • NCT00060944MANTRA Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a stomach or intestine condition that could make it difficult for your body to absorb milademetan, according to the doctor in charge of the study.You have received treatment with a specific type of medication called MDM2 inhibitor or trabectedin before.You had a severe infection in the past week that needed strong medicine given through a vein.You have had another type of cancer that needed treatment with medicine in the past two years, except if it was a localized cancer that has been completely cured.You have a type of cancer called liposarcoma that cannot be surgically removed because it would cause too much harm. The cancer has also spread to other parts of your body.
- Group 1: RAIN-32 (Milademetan)
- Group 2: Trabectedin
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the recommended use for RAIN-32?
"RAIN-32 can be used to therapeutically target rna-binding protein fus, metastatic leiomyosarcoma, and metastatic liposarcoma."
What other scientific papers have there been on RAIN-32?
"Currently, 18 RAIN-32 trials are ongoing and 2 of those are in Phase 3. The large majority of these clinical studies are taking place in Santa Monica, California; however, there are a total of 211 research sites for this RAIN-32."
How many potential participants are being sought for this research project?
"As of right now, this clinical trial is not enrolling any more patients. The study was first posted on 7/14/2021 and was last edited on 8/4/2022. If you are looking for other studies, there are 46 trials for liposarcoma and 18 RAIN-32 trials that are still recruiting patients."
Is RAIN-32 known to cause any serious side effects?
"There is some evidence of RAIN-32's efficacy, as well as multiple reports of its safety, so it has been given a score of 3."
Where are the trial sites for this experiment?
"There are 23 recruiting sites for this clinical trial, with notable locations including H. Lee Moffitt Cancer Center & Research Institute in Tampa, North carolina, Duke University School of Medicine, Duke Cancer Institute in Durham, and University of Miami Hospital & Clinics - Sylvester Comprehensive Cancer Center in Miami, Ohio."
Share this study with friends
Copy Link
Messenger